A share price of Blueprint Medicines Corp [BPMC] is currently trading at $89.73, down -1.09%. An important factor to consider is whether the stock is rising or falling in short-term value. The BPMC shares have gain 1.42% over the last week, with a monthly amount drifted -1.83%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
On March 17, 2025, Jefferies initiated with a Buy rating and assigned a price target of $135 on the stock. Scotiabank started tracking the stock assigning a Sector Outperform rating and suggested a price target of $150 on March 07, 2025. JP Morgan initiated its recommendation with a Overweight and recommended $126 as its price target on November 14, 2024. UBS started tracking with a Neutral rating for this stock on October 24, 2024, and assigned it a price target of $88. In a note dated May 14, 2024, Stephens initiated an Overweight rating and provided a target price of $140 on this stock.
Blueprint Medicines Corp experienced fluctuations in its stock price throughout the past year between $80.68 and $121.90. Currently, Wall Street analysts expect the stock to reach $124.33 within the next 12 months. Blueprint Medicines Corp [NASDAQ: BPMC] shares were valued at $89.73 at the most recent close of the market. An investor can expect a potential return of 38.56% based on the average BPMC price forecast.
Analyzing the BPMC fundamentals
Trailing Twelve Months sales for Blueprint Medicines Corp [NASDAQ:BPMC] were 508.82M which represents 103.41% growth. Gross Profit Margin for this corporation currently stands at 0.94% with Operating Profit Margin at -0.34%, Pretax Profit Margin comes in at -0.13%, and Net Profit Margin reading is -0.13%. To continue investigating profitability, this company’s Return on Assets is posted at -0.06, Equity is -0.22 and Total Capital is -0.19. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 1.57.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 88.57 points at the first support level, and at 87.40 for the second support level. However, for the 1st resistance point, the stock is sitting at 91.97, and for the 2nd resistance point, it is at 94.20.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Blueprint Medicines Corp [NASDAQ:BPMC] is 2.85. On the other hand, the Quick Ratio is 2.80, and the Cash Ratio is 0.39. Considering the valuation of this stock, the price to sales ratio is 11.27, the price to book ratio is 19.14.
Transactions by insiders
Recent insider trading involved Rossi Christina, CHIEF OPERATING OFFICER, that happened on Mar 24 ’25 when 2274.0 shares were sold. Officer, Christina Rossi completed a deal on Mar 24 ’25 to buy 9096.0 shares. Meanwhile, Director Albers Jeffrey W. sold 5766.0 shares on Mar 05 ’25.
